Our data demonstrated that the PE-EVOO treatment reduced the levels of phosphorylated NF-κB p65 in both RA patients and HS LPS-stimulated PBMCs, whereas the expression levels of total NF-κB did not change in both cases (Figure 5). This evidence concerns the gene NFKB1 and rheumatoid arthritis.